UY36070A - Triterpenoides con actividad inhibidora de la maduración de hiv - Google Patents

Triterpenoides con actividad inhibidora de la maduración de hiv

Info

Publication number
UY36070A
UY36070A UY0001036070A UY36070A UY36070A UY 36070 A UY36070 A UY 36070A UY 0001036070 A UY0001036070 A UY 0001036070A UY 36070 A UY36070 A UY 36070A UY 36070 A UY36070 A UY 36070A
Authority
UY
Uruguay
Prior art keywords
triterpenoids
inhibiting activity
hiv maturation
compounds
hiv
Prior art date
Application number
UY0001036070A
Other languages
English (en)
Inventor
Chen Yan
Chen Jie
Swidorski Jacob
Brian Lee Venables
Sin Ny
Nicholas A Meanwell
Alicia Regueiro-Ren
Richard A Hartz
Xu Li
Liu Zheng
Sing-Yuen Sit
Original Assignee
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53002809&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY36070(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Company Una Corporación Del Estado De Delaware filed Critical Bristol Myers Squibb Company Una Corporación Del Estado De Delaware
Publication of UY36070A publication Critical patent/UY36070A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C309/00—Sulfonic acids; Halides, esters, or anhydrides thereof
    • C07C309/63—Esters of sulfonic acids
    • C07C309/64—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms
    • C07C309/65—Esters of sulfonic acids having sulfur atoms of esterified sulfo groups bound to acyclic carbon atoms of a saturated carbon skeleton
    • C07C309/66—Methanesulfonates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D279/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D279/10—1,4-Thiazines; Hydrogenated 1,4-thiazines
    • C07D279/12—1,4-Thiazines; Hydrogenated 1,4-thiazines not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/04—Esters of boric acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Se divulgan compuestos que tienen propiedades que afectan los fármacos y biopropiedades, sus composiciones farmacéuticas y métodos de uso. En particular, se proporcionan triterpenoides que poseen actividad antiviral exclusiva como inhibidores de la maduración de HIV, como es representado por los compuestos de la fórmula I donde los sustituyentes y radicales son tales como se definen en las reivindicaciones.Estos compuestos son de utilidad para el tratamiento de HIV y sida.
UY0001036070A 2014-04-11 2015-04-09 Triterpenoides con actividad inhibidora de la maduración de hiv UY36070A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461978306P 2014-04-11 2014-04-11

Publications (1)

Publication Number Publication Date
UY36070A true UY36070A (es) 2015-10-30

Family

ID=53002809

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001036070A UY36070A (es) 2014-04-11 2015-04-09 Triterpenoides con actividad inhibidora de la maduración de hiv

Country Status (36)

Country Link
US (5) US9527882B2 (es)
EP (2) EP3129392B1 (es)
JP (1) JP6568202B2 (es)
KR (1) KR102411082B1 (es)
CN (1) CN106604909B (es)
AR (1) AR101077A1 (es)
AU (1) AU2015243500B2 (es)
BR (1) BR112016023414B1 (es)
CA (1) CA2944778C (es)
CL (1) CL2016002528A1 (es)
CR (1) CR20160472A (es)
CY (1) CY1123742T1 (es)
DK (1) DK3129392T3 (es)
DO (1) DOP2016000277A (es)
EA (1) EA030178B1 (es)
ES (1) ES2828705T3 (es)
HR (1) HRP20201645T1 (es)
HU (1) HUE051719T2 (es)
IL (1) IL248053B (es)
LT (1) LT3129392T (es)
MA (1) MA39374A1 (es)
MX (1) MX374543B (es)
NZ (1) NZ724644A (es)
PE (1) PE20161391A1 (es)
PH (1) PH12016501951B1 (es)
PL (1) PL3129392T3 (es)
PT (1) PT3129392T (es)
RS (1) RS60959B1 (es)
SG (2) SG10201709017PA (es)
SI (1) SI3129392T1 (es)
SM (1) SMT202000581T1 (es)
TW (1) TWI659964B (es)
UA (1) UA120927C2 (es)
UY (1) UY36070A (es)
WO (1) WO2015157483A1 (es)
ZA (1) ZA201606748B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX374543B (es) 2014-04-11 2025-03-06 Viiv Healthcare Uk No 4 Ltd Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo.
RU2018116772A (ru) * 2015-11-20 2019-12-20 ВАЙВ ХЕЛТКЕР ЮКей (N4) ЛИМИТЕД Композиции ингибитора созревания ВИЧ
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
EP3506902A4 (en) * 2016-08-31 2020-04-22 VIIV Healthcare Company COMBINATIONS AND USES AND TREATMENTS THEREOF
JP7436385B2 (ja) * 2018-04-24 2024-02-21 ヴィーブ ヘルスケア ユーケー（ナンバー５）リミテッド Ｈｉｖ成熟阻害活性を有する化合物
RS64113B1 (sr) * 2018-12-10 2023-04-28 Viiv Healthcare Uk No 4 Ltd Mesilatna so amino-lupan jedinjenja koja inhibitorno deluje na sazrevanje hiv
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
CN110981765A (zh) * 2019-11-07 2020-04-10 肇庆巨元生化有限公司 一种25-羟基维生素d3中间体的制备方法
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4906661A (en) 1981-11-12 1990-03-06 E. I. Du Pont De Nemours And Company Esters of aryloxypropanolamine derivatives
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
AR035311A1 (es) 1999-01-27 2004-05-12 Wyeth Corp Derivados de acido hidroxamico que contienen alquinilo, como inhibidores de las metalloproteinasas de matriz y de la tace, composicion farmaceutica y el uso de los mismos para la manufactura de un medicamento
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
EP1730163A4 (en) 2004-03-17 2009-12-30 Panacos Pharmaceuticals Inc Pharmaceutical salts of 3-O- (3,3-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008115281A2 (en) 2006-10-16 2008-09-25 Myriad Genetics, Inc. Compounds for treating viral infections
WO2012106190A1 (en) 2011-01-31 2012-08-09 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
WO2009020732A1 (en) * 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
JP2011511812A (ja) 2008-02-14 2011-04-14 バイロケム ファーマ インコーポレイテッド 新規１７βルパン誘導体
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
BR112012030810A2 (pt) 2010-06-04 2019-09-24 Bristol-Myers Squibb Company "c-28 amidas de derivados de ácido c-3 betulínico modificados como inibidores de maturação de hiv"
CA2801487C (en) * 2010-06-04 2017-12-05 Bristol-Myers Squibb Company Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
HRP20151212T1 (hr) 2011-01-31 2015-12-04 Bristol-Myers Squibb Company C-28 AMINI C-3 MODIFICIRANIH DERIVATA BETULINSKE KISELINE KAO INHIBITORI SAZRIJEVANJA HIV-a P
US8906889B2 (en) 2012-02-15 2014-12-09 Bristol-Myers Squibb Company C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
MX374543B (es) 2014-04-11 2025-03-06 Viiv Healthcare Uk No 4 Ltd Triterpenoides con actividad inhibidora de la maduración del virus de inmunodeficiencia humana, sustituidos en la posición 3 con un anillo no aromático que lleva un sustituyente haloalquilo.

Also Published As

Publication number Publication date
SMT202000581T1 (it) 2020-11-10
TWI659964B (zh) 2019-05-21
EP3129392A1 (en) 2017-02-15
US10780102B2 (en) 2020-09-22
MX2016013425A (es) 2017-05-02
KR20160147809A (ko) 2016-12-23
EP3750910A1 (en) 2020-12-16
US9527882B2 (en) 2016-12-27
PH12016501951B1 (en) 2021-02-19
AU2015243500A1 (en) 2016-10-27
IL248053B (en) 2020-04-30
ES2828705T3 (es) 2021-05-27
DOP2016000277A (es) 2017-02-28
DK3129392T3 (da) 2020-10-19
CA2944778A1 (en) 2015-10-15
US20170056420A1 (en) 2017-03-02
HRP20201645T1 (hr) 2020-12-25
MX374543B (es) 2025-03-06
PE20161391A1 (es) 2017-01-10
EA030178B1 (ru) 2018-06-29
CN106604909A (zh) 2017-04-26
SG11201608041QA (en) 2016-10-28
JP2017510659A (ja) 2017-04-13
BR112016023414A2 (es) 2017-08-15
HUE051719T2 (hu) 2021-03-29
LT3129392T (lt) 2020-11-10
CY1123742T1 (el) 2022-03-24
US10245275B2 (en) 2019-04-02
SG10201709017PA (en) 2017-11-29
JP6568202B2 (ja) 2019-08-28
IL248053A0 (en) 2016-11-30
PL3129392T3 (pl) 2021-04-06
TW201623324A (zh) 2016-07-01
US11464790B2 (en) 2022-10-11
UA120927C2 (uk) 2020-03-10
AR101077A1 (es) 2016-11-23
CR20160472A (es) 2017-03-10
BR112016023414B1 (pt) 2022-09-13
US20150291655A1 (en) 2015-10-15
NZ724644A (en) 2023-07-28
CA2944778C (en) 2022-06-14
SI3129392T1 (sl) 2020-11-30
KR102411082B1 (ko) 2022-06-17
AU2015243500B2 (en) 2017-03-30
US20190151336A1 (en) 2019-05-23
PT3129392T (pt) 2020-10-30
WO2015157483A1 (en) 2015-10-15
RS60959B1 (sr) 2020-11-30
EP3129392B1 (en) 2020-08-05
MA39374A1 (fr) 2018-06-29
ZA201606748B (en) 2018-05-30
EA201691760A1 (ru) 2017-02-28
US20200360404A1 (en) 2020-11-19
PH12016501951A1 (en) 2017-01-09
CL2016002528A1 (es) 2017-06-23
US20170340650A1 (en) 2017-11-30
CN106604909B (zh) 2019-02-15

Similar Documents

Publication Publication Date Title
NI201700096A (es) Derivados de 4h-pirrol[3, 2-c]piridin-4-ona
CL2018001685A1 (es) Compuestos heterociclicos como inmuno moduladores.
CL2018001230A1 (es) Tratamiento de osteoartritis
CL2017000712A1 (es) Pirimidinonas como inhibidores del factor xia
MX373247B (es) Nuevos derivados de octahidro-pirrolo[3,4-c]-pirrol y análogos del mismo como inhibidores de atotaxina.
MX2018016273A (es) Compuestos heterociclicos como inmunomoduladores.
MX386935B (es) Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades.
CL2017003067A1 (es) Piridinas sustituidas y método de uso
UY36311A (es) Indazoles sustituidos con bencilo
UY34657A (es) ?derivados macrocíclicos para el tratamiento de enfermedades?.
MX2017006302A (es) Derivados de adenina que son utiles en el tratamiento de enfermedades alergicas u otras afecciones inflamatorias.
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
UY36499A (es) Uso de picolinamidas como fungicidas
UY34201A (es) Compuestos de azaindol y métodos para el tratamiento de vih.
CL2016001973A1 (es) Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza.
EA201591406A1 (ru) C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич
UY36737A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
EA201492016A1 (ru) C-17 бициклические амины тритерпеноидов с ингибиторной активностью созревания вич
CO2017001528A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017001506A2 (es) Compuestos novedosos de pirimidina sustituidos
CO2017007325A2 (es) 2,4 diamino-quinolina sustituida como nuevos agentes anti-cancerigenos
CL2018001493A1 (es) Nuevos derivados de fenilo
MX386860B (es) Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cáncer.
UA120927C2 (uk) Тритерпеноїди, заміщені в положенні 3 неароматичним кільцем, яке несе галогеналкільний замісник, з інгібуючою активністю щодо дозрівання віл
UY35997A (es) Derivados de isoquinoleína, su procedimiento de preparación y las composiciones farmacéuticas que los contienen

Legal Events

Date Code Title Description
RDES Application refused

Effective date: 20230302